Disease · MONDO_0005420
Comparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 17 of 17
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Armour® Thyroid vs Levothyroxine: deaths from any cause | 1 of 141 | 1 of 143 | 284 | NCT04124705 | Trial comparisons |
| Armour® Thyroid vs Levothyroxine: serious adverse events | 4 of 141 | 7 of 143 | 284 | NCT04124705 | Trial comparisons |
| Radioiodine vs Control: deaths from any cause | 1 of 51 | 0 of 50 | 101 | NCT03880578 | Trial comparisons |
| Radioiodine vs Control: serious adverse events | 0 of 51 | 0 of 50 | 101 | NCT03880578 | Trial comparisons |
| Treatment Period: Tirosint Capsules vs Run-in Period: LT4 Tablets: deaths from any cause | 0 of 47 | 0 of 47 | 94 | NCT03094416 | Trial comparisons |
| Treatment Period: Tirosint Capsules vs Run-in Period: LT4 Tablets: serious adverse events | 1 of 47 | 2 of 47 | 94 | NCT03094416 | Trial comparisons |
| All Participants vs Participants Who Entered Maintenance Period: Proportion of Participants With Normalized TSH at End of Maintenance Period | 31 of 46 | 31 of 42 | 88 | NCT05823012 | Trial comparisons |
| All Participants vs Participants Who Entered the Maintenance Period: Proportion of Participants With Normalized TSH Throughout the Maintenance Period | 27 of 46 | 27 of 42 | 88 | NCT05823012 | Trial comparisons |
| 2 Tablet Increase vs 3 Tablet Increase: the Participants in Each Arm Who Required Levothyroxine Dose Adjustments (Either Increased or Decreased) Occurred to Maintain a Euthyroid State | 10 of 25 | 16 of 23 | 48 | NCT00230802 | Trial comparisons |
| 2 Tablet Increase vs 3 Tablet Increase: Proportion of Subjects With Abnormal Thyroid Stimulating Hormone Values When Following an Every 4 Week Monitoring Schedule During Pregnancy. | 25 of 25 | 23 of 23 | 48 | NCT00230802 | Trial comparisons |
| 2 Tablet Increase vs 3 Tablet Increase: Proportion of Patients in Each Treatment Arm Euthyroid Through Gestation | 24 of 25 | 21 of 23 | 48 | NCT00230802 | Trial comparisons |
| 2 Tablet Increase vs 3 Tablet Increase: serious adverse events | 0 of 25 | 0 of 23 | 48 | NCT00230802 | Trial comparisons |
| Levothyroxine Period vs Liothyronine Period: serious adverse events | 0 of 14 | 0 of 14 | 28 | NCT00106119 | Trial comparisons |
| Single Therapy vs Combination Therapy: deaths from any cause | 0 of 7 | 0 of 6 | 13 | NCT04782856 | Trial comparisons |
| Single Therapy vs Combination Therapy: serious adverse events | 0 of 7 | 0 of 6 | 13 | NCT04782856 | Trial comparisons |
Liquid Stable Levothyroxine (l-T4) TirosintSOL First, Then Oral Tablet Levothyroxine (L-T4) vs Oral Tablet Levothyroxine (L-T4) First, Then Liquid Stable Levothyroxine (L-T4) Tirosint-SOL: deaths from any cause | 0 of 2 | 0 of 4 | 6 | NCT04747275 | Trial comparisons |
Liquid Stable Levothyroxine (l-T4) TirosintSOL First, Then Oral Tablet Levothyroxine (L-T4) vs Oral Tablet Levothyroxine (L-T4) First, Then Liquid Stable Levothyroxine (L-T4) Tirosint-SOL: serious adverse events | 0 of 2 | 0 of 4 | 6 | NCT04747275 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005420/comparisons